The Semaglutide EVOKE Plus trial (NCT04777409) is a Phase 3 equivalent clinical trial evaluating the efficacy and safety of oral semaglutide (14 mg once daily) in patients with early Alzheimer's disease. Sponsored by Novo Nordisk, this trial represents one of the largest ongoing AD therapeutic studies, enrolling approximately 1,840 participants across multiple international sites[@clinicaltrialsgov2026][@novo].
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for Type 2 diabetes and obesity. This trial tests the hypothesis that GLP-1 receptor activation can exert neuroprotective effects in Alzheimer's disease through multiple mechanisms, including reduced neuroinflammation, improved insulin signaling, and enhanced mitochondrial function[@salcedo2022][@zhang2020].
Trial Identifier: NCT04777409
Status: Active, not recruiting (as of March 2026)
Start Date: 2021
Estimated Completion: 2025-2026
Phase: Phase 3
Enrollment: 1,840 participants
Sponsor: Novo Nordisk A/S
Rationale: GLP-1 Receptor Agonism in Alzheimer's Disease
The Metabolic-Inflammatory Hypothesis
Alzheimer's disease is increasingly recognized as a disorder with significant metabolic components. Type 2 diabetes mellitus is a established risk factor for AD, and insulin resistance is commonly observed in the brains of AD patients. This has led to the "type 3 diabetes" hypothesis, which proposes that AD represents a form of brain-specific insulin resistance[@de2008].
...
Overview
The Semaglutide EVOKE Plus trial (NCT04777409) is a Phase 3 equivalent clinical trial evaluating the efficacy and safety of oral semaglutide (14 mg once daily) in patients with early Alzheimer's disease. Sponsored by Novo Nordisk, this trial represents one of the largest ongoing AD therapeutic studies, enrolling approximately 1,840 participants across multiple international sites[@clinicaltrialsgov2026][@novo].
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for Type 2 diabetes and obesity. This trial tests the hypothesis that GLP-1 receptor activation can exert neuroprotective effects in Alzheimer's disease through multiple mechanisms, including reduced neuroinflammation, improved insulin signaling, and enhanced mitochondrial function[@salcedo2022][@zhang2020].
Trial Identifier: NCT04777409
Status: Active, not recruiting (as of March 2026)
Start Date: 2021
Estimated Completion: 2025-2026
Phase: Phase 3
Enrollment: 1,840 participants
Sponsor: Novo Nordisk A/S
Rationale: GLP-1 Receptor Agonism in Alzheimer's Disease
The Metabolic-Inflammatory Hypothesis
Alzheimer's disease is increasingly recognized as a disorder with significant metabolic components. Type 2 diabetes mellitus is a established risk factor for AD, and insulin resistance is commonly observed in the brains of AD patients. This has led to the "type 3 diabetes" hypothesis, which proposes that AD represents a form of brain-specific insulin resistance[@de2008].
GLP-1 receptor agonists like semaglutide address multiple aspects of this metabolic dysfunction:
Insulin sensitization: GLP-1R activation enhances insulin signaling in neuronal cells, improving glucose uptake and utilization
Anti-inflammatory effects: GLP-1 agonists suppress pro-inflammatory cytokine production and microglial activation
Mitochondrial protection: These agents help maintain mitochondrial function and reduce oxidative stress
Synaptic support: GLP-1 signaling promotes synaptic plasticity and neurogenesis
GLP-1 Receptors in the Brain
GLP-1 receptors are expressed in multiple brain regions relevant to Alzheimer's disease, including the hippocampus (critical for memory), cortex, and basal forebrain. Activation of these receptors triggers intracellular signaling cascades that exert neuroprotective effects[@salcedo2022][@zhang2020]:
Mermaid diagram (expand to render)
Previous Clinical Evidence
Phase 2 Liraglutide Trial (ELAD)
The Evidence for Liraglutide in Alzheimer's Disease (ELAD) trial was a landmark study evaluating liraglutide (another GLP-1 agonist) in patients with mild AD[@gejl2016]:
Key Findings:
Liraglutide treatment for 12 months was well-tolerated
Treatment group showed reduced decline in cerebral glucose metabolism
Trends toward better cognitive outcomes, though not statistically significant
Established safety profile for GLP-1 agonists in AD population
Preclinical Evidence
Multiple preclinical studies have demonstrated semaglutide's neuroprotective properties:
Reduced amyloid-beta-induced neuronal death in vitro[@bomba2018]
Improved cognitive performance in APP/PS1 transgenic mice[@pan2010]
Decreased neuroinflammation in mouse models of AD[@liu2015]
History of stroke or transient ischemic attack within 24 months
Current diagnosis of major depression or bipolar disorder
Type 1 diabetes or poorly controlled Type 2 diabetes (HbA1c >8.5%)
History of pancreatitis
History of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Contraindication to MRI
Prior exposure to semaglutide or other GLP-1 agonists
Participation in other interventional clinical trials within 12 months
Trial Sites
The EVOKE Plus trial is conducted at over 200 sites across North America, Europe, Asia, and Australia. Sites include major academic medical centers and specialized memory clinics.
Significance
The Semaglutide EVOKE Plus trial represents a critical test of the metabolic/inflammatory hypothesis of Alzheimer's disease. If positive, it could:
Validate a novel mechanism: Establish GLP-1 receptor agonism as an effective AD therapeutic approach
Expand treatment options: Provide a new oral treatment with favorable safety profile
Address unmet need: Offer treatment for patients with early AD, including those who cannot receive amyloid-targeting therapies
Enable combination approaches: Establish foundation for combination therapy with other AD drugs
The trial results are expected in 2025-2026 and will be pivotal for the field of metabolic therapies in neurodegeneration.
Cross-References
[GLP-1 Receptor Agonists in Neurodegeneration](/therapeutics/glp1-receptor-agonists) — Overview of the drug class
[Neuroinflammation in Alzheimer's Disease](/mechanisms/neuroinflammation) — Mechanism of neuroinflammation in AD
[Metabolic Dysfunction in Alzheimer's Disease](/mechanisms/brain-energy-metabolism) — Brain energy metabolism in AD
Novo Nordisk, Semaglutide EVOKE Plus Phase 3 Program in Alzheimer's Disease (n.d.)
[Salcedo I, Tweedie D, Li Y, Greig NH, Neuroprotective and disease-modifying effects of the triple GLP-1/GIP/glucagon receptor agonist DA-CH3 in an Alzheimer's disease model (2022)](https://pubmed.ncbi.nlm.nih.gov/35133184/)
[Zhang L, Zhang L, Li L, et al, Neuroprotective effects of GLP-1 receptor agonist on cognitive deficits and mitochondrial dysfunction in a mouse model of Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33248462/)
[de la Monte SM, Wands JR, Alzheimer's disease is type 3 diabetes-evidence reviewed (2008)](https://pubmed.ncbi.nlm.nih.gov/19013110/)
[Gejl M, Gjedde A, Egefjord L, et al, In Alzheimer's disease, 6-month treatment with GLP-1 analog liraglutide reduces brain glucose metabolism while preserving cognition (2016)](https://pubmed.ncbi.nlm.nih.gov/27113261/)
[Bomba M, Granzotto A, Castelli V, et al, GLP-1 receptor agonist exenatide protects against synaptic plasticity impairment in a mouse model of Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29940279/)
[Pan X, Gong N, Zhao J, et al, Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice (2010)](https://pubmed.ncbi.nlm.nih.gov/20385653/)
[Liu W, Jalewa I, Sharma M, et al, Neuroprotective effects of GLP-1 analog liraglutide in the 5xFAD mouse model of Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25993318/)
[McClean PL, Hölscher C, Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load and inflammation in a mouse model of Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25175556/)